| Document |
Document Title |
|
WO/2019/140188A1 |
Disclosed herein are dihydroceramide desaturase 1 (Des1) inhibitor compounds and compositions, which are useful in the treatment of diseases, such as metabolic disorders, where inhibition of Des1 is expected to be therapeutic to a patien...
|
|
WO/2019/130866A1 |
Provided is an active ray- or radiation-sensitive resin composition which has excellent storage stability and can enable a pattern with excellent LWR performance to be obtained. Also provided are a resist film, a pattern forming method, ...
|
|
WO/2019/127994A1 |
The present invention relates to a sacubitril sodium salt as represented by formula IV, a eutectic of sacubitril free acid and acetic acid, a crystal form of the eutectic and a preparation method for the crystal form, and a method for us...
|
|
WO/2019/122606A1 |
Disclosed are a new composition of lipoamino acids and alkanediols, a process for the preparation thereof, and a cosmetic or pharmaceutical composition resulting therefrom.
|
|
WO/2019/122601A1 |
Disclosed are a new composition of lipoamino acids and diols, a process for the preparation thereof, and a cosmetic or pharmaceutical composition resulting therefrom.
|
|
WO/2019/125930A1 |
Disclosed is a composition including a carbonyl-substituted alkene including a dicarbonyl compound having an alkylene group between the carbonyl groups. At least one carbonyl group of the dicarbonyl compound includes an amide group. Anot...
|
|
WO/2019/123125A1 |
The present disclosure relates to a process for the manufacturing of a compound comprising a (meth)acryloyl group, wherein the process comprises the steps of: a) providing a multi-screw extruder comprising a reaction chamber; b) providin...
|
|
WO/2019/123311A1 |
Subject-matter of the present invention is a process for preparing intermediates for the synthesis of optically active beta-amino alcohols by enzymatic reduction of the corresponding beta-amino ketones. Subject-matter of the invention ar...
|
|
WO/2019/108800A1 |
The invention relates to compounds that promote hematopoietic regeneration. The invention further relates to methods of promoting hematopoietic regeneration using the novel compounds of the invention.
|
|
WO/2019/105881A1 |
The invention relates to a novel and improved method for producing (3S)-3-(4-chlor-3-{[(2S,3R)-2-(4-chlorphenyl)-4,4,4-trifluor
-3-methylbutanoyl]amino}phenyl)-3-cyclo-propylpropanoic acid of the formula (I), to the compound of the formu...
|
|
WO/2019/102054A1 |
Non-glycosidic analogues of alpha-galactosylceramide of formula (I), wherein A, Z, Ra, Rb and Rc have the meaning indicated in the description, as NKT cell activators.
|
|
WO/2019/103433A1 |
The present invention relates to a novel pseudoceramide compound. More specifically, the present invention provides: a novel pseudoceramide compound represented by chemical formula 1, having skin moisturizing and barrier function restori...
|
|
WO/2019/099760A1 |
Aryl-substituted acetamide and pyrrolidin-2-one (γ-butyrolactam) derivatives have useful activity in the inhibition, prevention, or treatment of seizures. The derivatives may be useful in the treatment of epilepsy, including medically r...
|
|
WO/2019/096325A1 |
The present invention relates to a bisamide complex, and a method for quickly detecting organophosphate and carbamate pesticides. The complex prepared in the present invention can effectively detect trace quantities of organophosphate an...
|
|
WO/2019/094383A1 |
The present invention includes pharmaceutical composition comprising (2R,2R')- 3,3'-disulfanediyl bis(2-acetamidopropanamide)(diNACA) or D3-N-acetyl cysteine amide, or a physiologically acceptable salt thereof, having a deuterium enrichm...
|
|
WO/2019/093196A1 |
The present invention provides an amide compound which constitutes a wax component that is added to a resin to be molded, and which is able to be used over a wide processing temperature range because of the low melting point thereof, whi...
|
|
WO/2019/094772A1 |
Provided herein are small molecules comprising a first domain that binds to ASH1L and a second domain that facilitates ASH1L degradation. In particular, ASH1L-targeting proteolysis targeting chimeras (PROTACs) and methods of use thereof ...
|
|
WO/2019/090085A1 |
Provided herein are compounds of formula (I), compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases, disorders and conditions. (Formula I).
|
|
WO/2019/090074A1 |
Provided herein are compounds of formula (I) and (II), compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
|
|
WO/2019/090088A1 |
Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
|
|
WO/2019/076675A1 |
This invention relates to the finding that the inhibition of solute carrier family 6 member 2 (Slc6a2) exert a sympathomimetic effect outside the brain that promotes weight loss without concomitant hypophagia or hyperkinesia. Compounds f...
|
|
WO/2019/078185A1 |
The present invention addresses the problem of providing a cool-sensation imparter composition which contains a novel carboxylic acid derivative based on a carbon skeleton structurally differing from 1-menthol, and which is reduced in un...
|
|
WO/2019/077104A1 |
The present invention relates to a process for synthesis of a compound according to Formula (A): wherein R1 is a substituted or unsubstituted aryl having 6 to 20 carbon atoms; preferably substituted or unsubstituted phenyl; R2 is a strai...
|
|
WO/2019/077115A1 |
The present invention relates to synthetic capsaicin analogues, tautomers or salts thereof and their use as bioenhancers. The invention provides substituted capsaicyns for use as a bioenhancer, use as a bioenhancer on active substances, ...
|
|
WO/2019/076904A1 |
The application relates to compounds of formula (I) that show great affinity and activity towards the subunit α2δ of voltage-gated calcium channels (VGCC), especially the α2δ-1 subunit of voltage-gated calcium channels or dual activi...
|
|
WO/2019/079759A1 |
The present application provides malonamide compounds, and derivatives thereof (e.g., N-aryl malonamides (NAM), acetamides, oxalamides, and the like), that are useful, for example, for the treatment of acute, chronic/persistent, and/or r...
|
|
WO/2019/072864A1 |
The present invention pertains to a process for the preparation of polymorph form X of agomelatine, which comprises providing agomelatine, and crystallizing agomelatine in the presence of at least one of an acid and a salt thereof, and t...
|
|
WO/2019/071348A1 |
There is provide an extended release dosage form comprising a release modifying excipient comprising high amylose starch, cross-linked hydroxypropylated amylopectin, and a pre-gelatinized common starch; wherein the release modifying exci...
|
|
WO/2019/074749A1 |
Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder...
|
|
WO/2019/073471A1 |
Novel compounds usable in modulating an activity or function of a voltage-dependent potassium channel and/or of TRPV1 are provided. The compounds are represented by Formula I as described and defined in the specification.
|
|
WO/2019/074747A1 |
Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: (Formula (I)). Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated dise...
|
|
WO/2019/068912A1 |
A N-hydrocarbyldiamide composition comprising: a) a compound of formula (Ia), wherein R1 is selected from linear or branched or cyclic, saturated or unsaturated, hydrocarbon chains having from 1 to 40 carbon atoms, R2 is selected from li...
|
|
WO/2019/069697A1 |
The problem addressed by the present invention is solved by a liquid crystal composition and a liquid crystal display element including the same, the liquid crystal composition containing one or more types of a compound in which a unival...
|
|
WO/2019/063955A1 |
The present invention concerns the compounds of the following formula (I): (I) in which: - X represents an oxygen atom, a sulfur atom, a nitrogen atom or a CH radical, - The X--Y bond and Y are absent if X represents an oxygen or sulfur ...
|
|
WO/2019/067974A1 |
Compounds of the general Formula A-D-Y are disclosed with activity towards treating diseases related to inflammation, cancer, neurodegenerative diseases, and cardiovascular diseases. Pharmaceutical compositions, methods of making, and me...
|
|
WO/2019/051222A1 |
The present disclosure provides a benzene fused heterocyclic derivative of Formula (I): --̅-̅-̅ is a single or double bond; n is an integer of 0 or 1; A is -CH2-, -CH(OH)-, or - C(O)-; G is C or N; X is -CH2-, O, or -C(O)-; Y is alkyl...
|
|
WO/2019/046931A1 |
Compounds of general formula IA, IB and IC outlined below, including pharmaceutically acceptable salts, solvates and hydrates thereof. Such compounds and pharmaceutical compositions comprising them may be used in medical conditions invol...
|
|
WO/2019/047826A1 |
An aromatic derivative as represented by formula (I), a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising same, a preparation method therefor, and uses of the aromatic derivative and the pharmaceutically...
|
|
WO/2019/051184A1 |
Provided herein are acrylamide and acrylonitrile compounds and other compounds that may be produced from hydroxy amides and/or lactones. Provided herein are methods and systems to produce such compounds.
|
|
WO/2019/044946A1 |
A method for producing a compound represented by formula (C), the method comprising a step for converting a compound represented by formula (B) (wherein R1 represents an amino group protected by a protecting group) by intramolecular cycl...
|
|
WO/2019/042086A1 |
The present invention discloses a method and a device for purifying 2-nitro-4-acetamidoanisole and a product purified thereby. The 2-nitro-4-acetamidoanisole is prepared by using p-acetaminoanisole as a raw material to perform mixed acid...
|
|
WO/2019/041596A1 |
Disclosed are a compound for treating and/or preventing an immune disorder disease and an application thereof. The application provided by the present invention is specifically an application of a compound represented by formula I or for...
|
|
WO/2019/040992A1 |
The invention relates to oleoyl-lysophosphatidylinositol (oleoyl-LPI) and new synthetic derivatives thereof and uses thereof, and to pharmaceutical compositions comprising such compounds. The invention provides activators and/or up-regul...
|
|
WO/2019/046368A1 |
The present invention relates to compounds of formula (I) :, including any stereochemically isomeric form thereof, or pharmaceutically acceptable salts thereof, for the treatment of, for example, cancer.
|
|
WO/2019/038764A1 |
The present invention relates to lyso-diacylglyceryltrimethylhomoserine (lyso- DGTS) or derivatives thereof for use in the treatment of atherosclerotic cardiovascular disease, and further provides particular such lyso-DGTS derivatives.
|
|
WO/2019/040869A1 |
This invention relates to compounds for treating a protozoan parasitic infection and to pharmaceutical compositions comprising the compounds; and to methods of using the compounds and compositions to treat parasitic infections.
|
|
WO/2019/035453A1 |
Provided is a catalyst represented by general formula (1). In general formula (1), R1-R14 each independently represent a hydrogen atom or a substituent.
|
|
WO/2019/036678A1 |
Described herein, inter alia, are compositions and methods for modulating mu opioid receptor activity.
|
|
WO/2019/033219A1 |
A class of compounds useful in pharmaceutical compositions and methods for treating or preventing cancer is described. Analogs of Mycalolide B have been prepared and tested in breast and ovarian cancer cell lines. The compounds show util...
|
|
WO/2019/036000A1 |
Compounds are provided having the following structure (I) or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1a, R1b, R2a, R2b, R3a, R3b, R4a, R4b, R5, R6, R7, R8, L1, L2, G1, G2, G3, a, b, c and d are as d...
|
